DailyIQ
Last updatedUpdating…

STE·STERIS plc

$217.27
-0.50 (-0.23%)
After Hours
High
$220.01
Open
$217.65
Market Cap
21.25B
52W High
$269.44
Low
$215.70
P. Close
$217.27
P/E
26.40
52W Low
$195.14
Fwd P/E
17.75
DailyIQ Est.
$265.86
Inst. Ownership
0.0%
Short Interest
2.95%
Days to Cover
4.2
Div. Yield
0.90%
Next Ex-Div
~Dec 3
Div. Growth
20+ yrs
Technical Score (1D)
25
BEARISH
News Sentiment
81
BULLISH
On Oct 13, Steris announced it had completed a $2.1 billion acquisition of Xodus Medical, adding Xodus’s high‑margin consumable products such as the Pink Pad patient‑positioning system and the See Sharp laparoscopic cleaning device to its portfolio. The transaction was expected to strengthen Steris’s operating‑room consumables revenue and broaden its surgical safety product line, creating synergies through cross‑selling and expanded distribution channels. The deal was also projected to boost Steris’s position in the surgical safety market by expanding its range of safety devices. On the same day, SeekingAlpha highlighted Steris as a stable and attractive investment, noting that the company trades at a reasonable 18‑19x forward earnings multiple and that its fundamentals support a positive outlook. The analyst expressed confidence in Steris’s current performance and future prospects, identifying no material risks or negative catalysts.
LOW TARGET
$232 +6.8%
1 analysts
MEAN TARGET
$262 +20.7%
11 analysts
HIGH TARGET
$280 +28.9%
6 analysts
PRICE RANGE
$232.00 - $280.00
SB / B / H / S / SS
3/8/5/1/1
DAILYIQ EST.
$265.86 (+22.4%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
United States
Website
Symbol
STE
Description
STERIS plc is a global provider of infection prevention solutions, serving the healthcare, pharmaceutical, and medical device industries. The company operates through three primary segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. STERIS's Healthcare segment offers a broad portfolio of products and services, including cleaning and sterilization equipment, accessories, and related services for hospitals and other healthcare facilities. Through AST, STERIS provides contract sterilization services and testing to medical device and pharmaceutical manufacturers, along with integrated sterilization equipment. The Life Sciences segment supplies consumable products, such as disinfectants and sterilants, and equipment for pharmaceutical and research applications, complemented by service offerings. Founded in 1985, STERIS is headquartered in Mentor, Ohio.
Bought (1Y)
0 shares
$0
Sold (1Y)
27,003 shares
$5.0M
Burton Karen LSr. Vice Pres., CFO
Tax Withholding228 shares2026-10-01
Sohi Mohsen-
Option Exercise4,058 shares2026-08-12
Sohi Mohsen-
Sell4,058 shares2026-08-12
Sohi Mohsen-
Option Exercise4,058 shares2026-08-12
Alegria Esther M.-
Award/Grant512 shares2026-08-10
79/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
44.2%
Net Margin
13.2%
Revenue CAGR
9.5%
Current Ratio
2.09x
Debt / Equity
0.27x
Return on Equity
10.9%
Earnings Summary
STERIS plc is a global provider of infection prevention solutions, serving the healthcare, pharmaceutical, and medical device industries through its Healthcare, Applied Sterilization Technologies, and Life Sciences segments. The company’s business model centers on sterilization equipment, contract services, and consumable products, positioning it within the broader medical devices sector. In the most recent quarters, STERIS delivered solid earnings growth: Q4 2024 EPS of $2.32 versus an estimate of $2.32, and Q1 2025 EPS of $2.74 beating the $2.60 estimate; revenue rose from $1.37 billion in Q4 2024 to $1.48 billion in Q1 2025, a 8.5% increase. Q2 2025 EPS of $2.34 exceeded the $2.26 estimate, while revenue dipped slightly to $1.39 billion, a 6.3% decline from Q1 2025. Q3 2025 EPS of $2.47 beat the $2.35 estimate, and revenue climbed to $1.46 billion, a 4.5% rise from Q2 2025. The company has consistently outperformed earnings estimates in the last four quarters, with revenue growth in three of those periods despite a modest Q2 2025 revenue decline. Historically, STERIS has maintained a steady YoY revenue growth trajectory, with EPS beats in most quarters and occasional revenue misses that are offset by strong service‑based recurring income. Recent news highlights a 22% decline from its 52‑week high, reflecting broader healthcare weakness and investor concerns over a muted earnings miss and a thin product pipeline; the company’s backlog grew 7.7% YoY to $553.9 million, offering some revenue stability.

EPS

EstBeatMiss
$2.18$2.37$2.56$2.75$2.94Q1'25Q2'25Q3'25Q4'26Q1'27Q3'26
QtrEstActual+/−
Q3'26$2.56 - -
Q1'27$2.53$2.59+2.5%
Q4'26$2.85$2.83-0.7%
Q3'25$2.35$2.47+5.1%
Q2'25$2.26$2.34+3.4%
Q1'25$2.60$2.74+5.4%

Revenue

EstBeatMiss
$1.4B$1.4B$1.5B$1.6B$1.6BQ1'25Q2'25Q3'25Q4'26Q1'27Q3'26
QtrEstActual+/−
Q3'26$1.5B - -
Q1'27$1.5B$1.5B-1.3%
Q4'26$1.6B$1.6B-1.4%
Q3'25 - $1.5B -
Q2'25 - $1.4B -
Q1'25 - $1.5B -

Market Data

STE Stock Snapshot

BEARISH25/100
$217.26−$0.01 (0.0%)
Market cap
21.25B
P/E ratio
26.4
Day range
$215.70 – $220.01
News sentiment
81/100 · Bullish
Analyst target
$262.14 (+20.7%)
Consensus
Buy · 18 analysts
52-week range+11.3% off low · -19.4% from high
$195.14$269.44
Price $217.26 DailyIQ Est. $265.86

STE's technical picture is under pressure, with momentum working against price. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What STE's own history says about today's numbers

Realized volatility (21d)
14.4% 19th pct
Below its peak
-18.3%
vs 200-day average
-3.2%
Up days (1y)
48%

STERIS plc is currently running 14.4% annualised volatility over the last 21 sessions. Measured against STE's own 13 years of daily returns rather than a market-wide average, that is the 19th percentile — unusually subdued by its own history, against a typical reading of 20.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

STE is trading -18.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -15.4%, and the deepest was -36.5% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -3.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 16th percentile — a narrower gap than it typically runs. Over the past year STE closed higher on 48% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, STE finished the month higher 9 of 14 times, with a median return of +1.1% and an average of +2.4%. Its strongest month historically has been May at +4.3% on average, its weakest September at -1.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: STE has opened more than 2% away from the prior close in 67 of 3,268 sessions (2.1% of the time), with the largest gaps running +6.1% and -8.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, STE moved an average of 1.8% in the session after earnings, closing higher 3 of those 3 times, with a median move of +0.8% and a largest of +4.4%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against STE's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of STE's sector?

STERIS plc sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, STE ranks 2nd of 15 tracked industries, leading.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#2 of 15

Options Market

What is the options market pricing for STE?

CallsPuts

For STERIS plc's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.53), with at-the-money implied volatility around 44.3%. The options market is pricing roughly a ±3.6% move by that expiry — a range of about $201.05–$215.97.

Put/call ratio (2026-10-16)
0.53
ATM implied volatility
44.3%
Total open interest
1,479
Expected move by 2026-10-16
±3.6% ($201.05–$215.97)

Analyst Rating Changes

Are analysts turning bullish or bearish on STE?

UBS most recently reiterated its rating on STERIS plc to Buy on Aug 7, 2026 with a price target of $270 (from $275). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBS — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 7, 2026UBSMaintainedBuy$275 → $270
Aug 7, 2026Piper SandlerReiteratedOverweight$270 → $275
Jul 28, 2026UBSInitiatedBuy$275
May 13, 2026KeybancMaintainedOverweight$291 → $269
Aug 8, 2025Morgan StanleyMaintainedOverweight$276 → $295
Jul 22, 2025KeybancMaintainedOverweight$277 → $288
Jul 15, 2025Morgan StanleyUpgradeEqual-Weight → Overweight$260 → $276
May 29, 2025JefferiesInitiatedHold$263
May 19, 2025Morgan StanleyMaintainedEqual-Weight$240 → $260
May 16, 2025JMP SecuritiesMaintainedMarket Outperform$265 → $280
May 15, 2025Stephens & Co.ReiteratedOverweight$250
May 12, 2025Morgan StanleyMaintainedEqual-Weight$230 → $240

Peers & ETF holders

STE peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

81/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Steris announced a $2.1 billion acquisition of Xodus Medical, adding high‑growth, high‑margin consumable products such as Pink Pad positioning devices and the See Sharp laparoscopic cleaning system. The deal is expected to boost Steris’ operating‑room consumables revenue and support its goal of expanding the healthcare consumables portfolio. Xodus’ portfolio complements Steris’ existing sterilization and disinfection equipment, and the company projects annual sales of $245 million for Xodus this year. The transaction is anticipated to close within the current fiscal year, potentially enhancing Steris’ revenue growth trajectory.
What did this article say?
Steris announced on October 13 that it would acquire Xodus Medical for $2.1 billion in cash, a transaction that will broaden its surgical device offerings. The deal adds Xodus’s advanced robotic and imaging solutions to Steris’s existing portfolio, positioning the company to capture a larger share of the growing surgical market. The acquisition is expected to generate synergies and accelerate product development, reinforcing Steris’s competitive stance in the medical device sector.
What did this article say?
Steris was highlighted as a stable and attractive investment by SeekingAlpha on October 13. The analyst noted that the company’s shares trade at a reasonable 18-19x forward earnings multiple. The commentary emphasized robust fundamentals and a positive outlook for the business. No material risks or negative catalysts were identified in the analysis. The overall tone reflected confidence in the company’s current performance and future prospects.
What did this article say?
On October 12, STERIS (STE) announced it had entered into an agreement to acquire Xodus Medical, a developer of surgical safety solutions. The deal positions STE to broaden its infection prevention offerings and strengthen its presence in the operating room market. The acquisition is expected to enhance STE’s product portfolio and generate additional revenue streams. The transaction is viewed as a strategic expansion that could drive future growth for STE.
What did this article say?
Steris Inc. (STE) saw its shares decline 14.3% year‑to‑date, prompting analysts to question whether the current valuation aligns with the company’s cash‑flow prospects. The firm’s business model relies heavily on recurring revenue from equipment services and sterilization offerings, which generate predictable cash flows.
What did this article say?
Steris (NYSE:STE) conducted its first‑quarter 2027 earnings conference call on October 9. The company provided a full transcript of the discussion, outlining its financial performance and operational highlights for the quarter. No new guidance or material corporate actions were disclosed during the call. The transcript offers investors a detailed view of the company’s current performance metrics and management commentary.
What did this article say?
During the Morgan Stanley 24th Annual Global Healthcare Conference, STERIS CEO Daniel Carestio highlighted the company’s progress over the past five years, emphasizing operational efficiencies and product portfolio expansion. He noted that investors may still underappreciate the company’s focus on digital integration and supply chain resilience. No new financial guidance or material corporate actions were disclosed, and the presentation largely reiterated existing strategic themes. The remarks reinforce STE’s current trajectory without indicating any immediate upside or downside catalysts.
What did this article say?
Representative April McClain Delaney sold between $100,001 and $250,000 of STERIS plc (STE) stock on August 25th, as disclosed in a federal filing. The sale represents a modest outflow relative to the company’s market capitalization and does not indicate a large-scale divestiture. However, the timing and size of the trade may be interpreted by investors as a lack of confidence in STE’s near‑term prospects. The transaction adds to a broader pattern of political insider selling that often precedes short‑term price pressure.
What did this article say?
Steris (STE) reported first‑quarter fiscal 2027 earnings that beat estimates, with adjusted EPS up 10.7% YoY and GAAP EPS surpassing consensus. Revenue grew 7.3% to $1.49 billion but fell short of analyst expectations by 0.83%, indicating pricing pressure. The company’s backlog expanded 7.7% YoY to $553.9 million, suggesting future revenue stability. These results provide a modest upside catalyst, but the revenue miss tempers enthusiasm for a strong rally.

Technical Analysis

Real-time indicators across multiple timeframes

25
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
5 tracked managers · $5.91M combined position · 4 adding, 1 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Brevan Howard Capital Management LP▲ Buy20,6540.02%$4.35M2026-08-14
Schonfeld Strategic Advisors LLC▲ Buy2,8820.00%$606.9K2026-08-14
Graham Capital Management, L.P.▲ New2,8500.00%$600.1K2026-08-14
Ancora Advisors LLC▲ Buy1,6880.00%$355.4K2026-08-14
Winton Group Ltd▼ Sold out00.00%$02026-08-07
Q2 2026 flow:22.7K sh bought ($4.78M)3.1K sh sold ($676.7K)net +19.6K sh (+$4.10M)
Congressional Trading Activity
19 disclosed trades · ~$343.5K est. traded value · 10 buys, 9 sells
MemberChamberStateTypeAmountTradedFiled
Kevin HernHouseOK01▼ Sell$15K - $50K2026-09-152026-09-25
April McClain DelaneyHouseMD06▼ Sell$100K - $250K2026-08-252026-09-09
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-07-312026-08-03
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-07-292026-08-03
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-07-272026-08-03
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-07-242026-08-03
Jared MoskowitzHouseFL23▼ Sell$1K - $15K2026-07-132026-08-27
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-05-132026-06-08
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-05-112026-06-08
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-05-012026-05-08
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2026-04-302026-05-06
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2026-03-162026-04-06
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-02-102026-03-09
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2026-02-062026-03-10
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-09-182025-10-06
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-09-112025-10-06
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-06-262025-07-02
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Susan M. CollinsSenateME▼ Sell$1K - $15K2014-07-232015-07-20